Healthcare Industry News: Genomic Profiling
News Release - February 20, 2007
PDL BioPharma Announces New Chief Medical Officer and Appoints Chief Scientific Officer to Its Board of DirectorsFREMONT, Calif., Feb. 20 (HSMN NewsFeed) -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that industry veteran Mark A. McCamish, M.D., Ph.D. will join the company as senior vice president and chief medical officer on February 21, 2007. The company also announced the promotion of Richard Murray, Ph.D. to executive vice president and chief scientific officer. Dr. Murray was also appointed to the company's board of directors.
Dr. McCamish brings over 25 years of experience in corporate management, clinical and pharmaceutical research, and academics to PDL's senior management team. He will oversee all clinical development functions and programs at the company, including regulatory affairs, safety, clinical development, clinical operations and biometry/data management.
Dr. Murray joined PDL as vice president of research in April 2003 and was named senior vice president and chief scientific and technical officer in September 2005. In his new roles, Dr. Murray will continue to oversee the company's antibody discovery, process sciences, manufacturing and preclinical development activities, in addition to participating as a PDL board member.
"With Mark joining our organization and Rich continuing to head our research and development efforts, we now have stronger leadership in place to support and drive the long-term growth of our development programs," said Mark McDade, chief executive officer, PDL BioPharma. "Mark's proven track record in development at some of the healthcare industry's largest and most successful organizations makes him an ideal choice to lead PDL's exciting clinical programs focused on cancer, autoimmune and inflammatory diseases and cardiovascular disorders. We believe his knowledge in the area of pharmacoGenomic Profiling, based on his recent experience at Perlegen, will aid the design of more informative and effective clinical trials at PDL."
Dr. McCamish comes to PDL from Perlegen Sciences, where, since 2003, he served as chief medical officer and vice president of clinical development of the privately-held pharmacogenomics company focused on applying personalized medicine technology to drug development.
Previously, he held various senior-level development positions at Amgen, Inc., including responsibility for international development activities and new product development strategies in various therapeutic areas. Prior to his tenure at Amgen, Dr. McCamish held broad responsibilities at Abbott Laboratories, including national and international clinical research supporting the launch of multiple products, interfacing with marketing and sales departments and competitive product evaluation. Dr. McCamish also has years of experience in academia at Ohio State University, the University of California at Davis and Michigan State University.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL's research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Source: PDL BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.